Oncolytics Biotech Inc T.ONC

Pela + CAR-T Presentation at the CAR-TRC Summit on Feb. 22nd

[Proboscises]

Houra Loghmani will be making her 30 minute presentation at the CAR-TCR Summit on Wednesday, Feb. 22nd at 5:00 pm London time.  Below is an outline of her presentation as provided by the conference organizers.  I'm curious if ONC/Y will release any information from this presentation or if Richard Vile will be participating.    

The last presentation of pela plus CAR-T data was from a large poster on Feb. 12, 2021 (https://d1io3yog0oux5.cloudfront.net/_e3c6ba6001202bcd28648072a00a7975/oncolyticsbiotech/db/343/2550/pdf/CAR+TCR+POSTER.pdf), a press release from Feb. 23, 2021(https://www.oncolyticsbiotech.com/press-releases/detail/527/oncolytics-biotech-reports-preclinical-data-demonstrating), and an excellent KOL webcast on April 12, 2021.  All are available on the Oncolytics Biotech website.

Given that these previous presentations were from almost 2 years ago I'm curious if new  discoveries will be discussed since the Vile Lab at the MAO Clinic has presumably been actively working on the pela + CAR-T combo. We shall see.  Maybe more info on the best timing for effective therapy with Pela and CAR-T will be discussed.  Also, the previous data was based on Pela + CAR-T administered to mice with implanted melanoma.  I see in the agenda for Houra's presentation they will also be discussing Pela-CAR-T and glioma.  

I do hope we are given some information following the conference.


Enhancing Efficacy in the Clinic with Alternative Immunomodulation Strategies

5.00 Combining CAR-T Therapies with an Oncolytic Virus to Improve Therapeutic Response

• Combining CAR-T therapy with the administration of oncolytic virus intravenously

• Potentiating CAR-T cell efficacy against solid tumour models of melanoma and glioma

• Stimulating the native TCR to give rise to enhanced proliferation, CAR-directed anti-tumour function and distinct memory phenotypes which are readily re- activated by virus administration

  Houra Loghmani, Senior Scientist, Translational Oncology, Oncolytics Biotech

[inthno]

I could be wrong but if the presentation has information that is presented that is not already in the public domain then onc will be required to pr the information as this Information has to be available to all shareholders and not just a select few. We shall know soon enough.

[canadafan]

My guess is that they will be presenting existing information. As you keyed into. They can not present " new" or " material" information to a select few. So, if we don't see or hear about a N.R. Tomorrow am, then obviously existing data, being presented to a new crowd. in of itself, not good or bad. I have seen, with other biotechs, well published data represented. The

[JohnnyYeg]

I'm wondering if they are simply doing a general "informational" presentation on CAR-T and oncolytic viruses, hence no NR being released regarding it - it's about the technology and concept and not about a trial specific data reveal....

[canadafan]

I agree Johnny  the poster barely if at all mentions Pelareorep. a general CAR- t thing

[jimsenior]

@probo. Search - Re-purposing Oncolytic Virotherapy to Reinvigorate CAR T Cell Therapy for Solid Tumors. I shall let you ascertain what may said Wednesday. I would guess one of the top teams anywhere would at least tell us about their current work. I do like the word re-purposing; it says a lot I think. Cheers